With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Six companies, including Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX), are set to join the Nasdaq 100 ...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

Cantor Fitzgerald analyst Olivia Brayer initiated coverage with a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $165.00. The company’s shares closed ...